MEDI-528 9 mg/kg

BIOLOGICAL3 trials

Sponsors

MedImmune LLC

Conditions

AsthmaHealthy

Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

CompletedNCT00116168

MedImmune LLCHealthy

Start: 2005-06-30End: 2006-07-31Updated: 2013-12-11

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

CompletedNCT00192296

MedImmune LLCAsthma

Start: 2004-08-31End: 2005-03-31Updated: 2014-03-06

Phase 2

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

CompletedNCT00394654

MedImmune LLCAsthma

Start: 2006-11-30End: 2008-01-31Updated: 2013-12-11

Related Papers

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

2009-04-0154 citations